Liranaftate (CAS 88678-31-3) Supplier Information and Product Details

Liranaftate is a third-generation dithiocarbamate antifungal agent. It belongs to the squalene cyclooxygenase inhibitors, hindering the synthesis of ergosterol in fungal cell membranes. Its antifungal activity is 8 times that of tolnaftate and more effective than clotrimazole against dermatophytes. It is used to treat various fungal infections, including tinea capitis, ringworm, athlete's foot, onychomycosis, jock itch, tinea versicolor, and vulvovaginal candidiasis.

Frequently Asked Questions about Liranaftate

Q: What is the mechanism of action of Liranaftate?

A: Liranaftate works by inhibiting squalene epoxidase, which blocks ergosterol biosynthesis in fungi. This mechanism specifically targets fungal cell membranes without affecting mammalian cholesterol biosynthesis at therapeutic doses.

Q: How does Liranaftate compare to other antifungal agents?

A: Liranaftate has been found to be significantly more active than tolnaftate against several dermatophytes, including Trichophyton mentagrophytes, and certain yeasts like Cryptococcus neoformans. However, it is inactive against various Gram-positive and negative bacteria.

Q: What are the common formulations of Liranaftate?

A: Liranaftate is commonly formulated as a cream, typically in 1% or 2% concentrations. This topical formulation has shown good tolerability in clinical trials with no observed systemic absorption.

Q: Are there any safety concerns with Liranaftate?

A: Liranaftate has shown a favorable safety profile in various toxicity studies. Reproductive toxicity tests in rats showed no toxic effects at doses up to 100 mg/kg. Mutagenicity tests were negative, and teratogenicity studies showed no toxic effects to fetal rats at doses up to 100 mg/kg.